Enbrel, Etanercept News

A Swedish study has concluded that rheumatoid arthritis patients did not experience an increased cancer risk in the first 6 years of treatment with TNF blockers .

During the past decade, a new class of drugs, called TNF inhibitors, has improved the lives of tens of thousands of people who suffer from painful autoimmune diseases including rheumatoid arthritis, psoriatic arthritis, and Crohn's disease.

Oct. 29, 2009 -- Rheumatoid arthritis patients who take the biologic drugs Remicade , Humira , and Enbrel do not appear to have an increased risk for developing cancer in the first few years of use, researchers in Sweden report.

Treatment with tumor necrosis factor blockers doesn't increase rheumatoid arthritis patients' risk of cancer, new research has found.

A recent study by Swedish researchers found that rheumatoid arthritis patients did not experience an elevated cancer risk in the first 6 years after starting anti-tumor necrosis factor therapy.

Last week, Pfizer, the world's largest biopharmaceutical company, officially completed its merger with Wyeth, which produces some of the world's top-selling medicines, including Enbrel for rheumatoid arthritis and Prevnar, a vaccine against pneumococcal disease.

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the continued uptake of marketed and emerging TNF-alpha inhibitors and interleukin inhibitors will drive the psoriasis drug market to increase from $3 billion in 2008 to $5.2 billion in 2018 in the United States, France, ...

Cephalon, Inc. and BioAssets Development Corporation , a privately held biopharmaceutical company, today announced that the companies have signed an agreement that will provide Cephalon with an option to acquire BDC.

Back in the dim days of black-and-white television, one over-the-counter product that was frequently advertised claimed to help "the heartbreak of psoriasis." The phrase is no longer heard in commercials, but the heartbreak is still there.

As a treatment for rheumatoid arthritis, there is "moderate-level" evidence that the immunomodulator abatacept is safe and effective, conclude the co-authors of a Cochrane Intervention Review posted online October 4. Abatacept inhibits the co-stimulation of T cells and disrupts the inflammatory chain of events that lead to joint inflammation, pain ...

Main Category: Arthritis / Rheumatology Also Included In: Clinical Trials / Drug Trials Article Date: 23 Oct 2009 Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that tumor necrosis factor -alpha inhibitors will continue to dominate first- and second-line biologic ...

Back in the dim days of black-and- white television, one over-the-counter product that was frequently advertised claimed to help "the heartbreak of psoriasis." The phrase is no longer heard in commercials, but the heartbreak is still there.

Oct 19, 2009 - Idera Pharmaceuticals, Inc. today announced the presentation of preclinical data from studies of IMO-3100 in combination with Enbrel in a mouse model of arthritis.

Main Category: Arthritis / Rheumatology Also Included In: Clinical Trials / Drug Trials ; Conferences ; Pharma Industry / Biotech Industry Article Date: 20 Oct 2009 - 1:00 PDT New long-term data from two pivotal, Phase 3 clinical trials showed that patients with active rheumatoid arthritis receiving SIMPONI every four weeks achieved sustained ...

SCI Corporation announced today the presentation of new rheumatoid arthritis data at the American College of Rheumatology's annual meeting in Philadelphia, PA.

A rheumatoid arthritis treatment that can cost patients thousands of dollars less annually is as effective as another regimen that many doctors believe to be more potent, a University of Nebraska Medical Center physician says.

In the first and largest researcher-initiated blinded study comparing the effectiveness of a drug treatment for rheumatoid arthritis, researchers found a $1,000 treatment and a $25,000 treatment to have the same effectiveness.

Pfizer Inc.'s $68 billion purchase of Wyeth will close today after antitrust regulators in the U.S. and Canada cleared the deal, which will make Pfizer the world's largest drugmaker by revenue.

The world's biggest drugmaker will become the owner today of several consumer health products long manufactured in the Richmond area.

People with psoriasis and/or psoriatic arthritis who are taking biologic or non-biologic immunosuppressive medications should receive the inactived forms of both seasonal influenza and H1N1 vaccines as soon as possible, according to a recommendation from the National Psoriasis Foundation.